The genetic mechanisms underlying the progression to the metastatic phenotype of lung cancer are poorly understood. We recently showed that small cell lung cancer (SCLC) and metastasizing squamous cell carcinomas are characterized by an increased incidence of allelic loss on chromosome 10q. In the present study we performed a deletion mapping using 24 polymorphic markers on chromosome 10q22-q26 in 39 squamous cell carcinomas (SCC) of the lung identifying 14 metastatic carcinomas (74%) and three non-metastatic SCC (15%) with allelic imbalance. The allelotype analysis indicated three regions of allelic loss that were clustered at the loci Afm086/D10S541, D10S185 and D10S1782/D10S169. A localized microsatellite instability was observed in two carcinomas for the markers D10S1686 and D10S1782. In addition the PTEN/MMAC1 gene was analysed by direct DNA sequencing and Southern blot analysis in 25 and 28 carcinomas, respectively, without detecting any genomic alterations. Similarly, no altered transcript was detected in 15 tumor cell lines and 20 primary tumors by Northern blot analysis or RT ± PCR. In summary, three distinct regions of allelic imbalance were identi®ed suggesting that multiple tumor suppressor genes on chromosome 10q contribute to tumor progression and metastases formation of lung cancer.
Introduction
Lung cancer has the highest incidence of cancerrelated death throughout the world (Pisani et al., 1993) . Considerable progress has been made in de®ning genetic defects of precursor lesions (Gazdar et al., 1994; Thiberville et al., 1995) . However, the advanced carcinoma is the major problem for the clinician. The majority of lung cancers is either not resectable at the time of diagnosis or has already spread to distant organs. The high malignancy is re¯ected by the multitude of genetic changes that have been described by cytogenetics, allelotype studies and CGH (Testa and Siegfried, 1992; Sato et al., 1994; Petersen et al., 1997a,b) . So far, no genetic progression model has been established and some ®ndings are still controversial. However, previous studies suggested that deletions on chromosome 3p are associated with tumor initiation followed by imbalances on chromosomes 9p, 13q and 17p whereas tumor progression is characterized by additional changes, e.g. allelic loss on chromosomes 2q, 5q, 18q and 22q (Gazdar et al., 1994; Thiberville et al., 1995; Fong et al., 1995; Shiseki et al., 1996) .
Allelic loss on chromosome 10q occurs during development and progression of a wide variety of human malignancies including renal cell carcinoma (Morita et al., 1991) , non-Hodgkin's lymphoma (Speaks et al., 1992) , glioblastoma (Karlbom et al., 1993; Rasheed et al., 1995) , meningioma (Rempel et al., 1993) , malignant melanoma (Herbst et al., 1994) , endometrial cancer (Peier et al., 1995) , prostate cancer (Komiya et al., 1996; Gray et al., 1996) , bladder carcinomas (Cappellen et al., 1997) and squamous cell carcinomas of the head and neck (BockmuÈ hl et al., 1997) . Human chromosome 10 transfer into a glioblastoma derived cell line resulted in suppression of tumorigenic properties in vitro and in vivo (Pershouse et al., 1993) and in particular in metastasis suppression in a rat prostate cancer cell line (Nihei et al., 1995) . We recently showed that LOH on chromosome 10q is associated with the metastatic phenotype of SCLC and SCC of the lung (Petersen et al., 1998) .
The aim of the present study was to further re®ne the regions on chromosome 10q potentially harbouring tumor suppressor genes by performing an allelotype study in 39 lung SCC using 24 microsatellite polymorphisms. Additionally, we analysed the PTEN/MMAC1 gene which is located in a region of frequent LOH and has been identi®ed as a candidate gene being involved in the progression of many tumor types . Our study revealed LOH particularly in metastatic lung SCC with three distinct regions of allelic imbalance suggesting the presence of several tumor suppressor genes on chromosome 10q. We failed to identify mutations of the PTEN/MMAC1 gene indicating that other genes mediate the aggressive phenotype of advanced lung SCC.
Results

Deletion mapping
The allelotype analysis on chromosome 10q identi®ed 17 out of 39 cases with at least one allelic imbalance. The analysis of these cases is shown in Figure 1a suggesting three regions of minimal allelic imbalance. Region I was located between the markers Afm086 and D10S541 as indicated by the cases L30, L35, L29 and L37. Region II was centered at the marker D10S185 substantiated by the cases L33, L31, L39, L38 and L37. Region III was observed between the markers D10S1782 and D10S169 as indicated by the cases L32, L56, L29, L43. On the basis of the published data the size and cytogenetic localization of these regions would be as follows: Region I, 9 cM, 10q23; Region II, 4 cM, 10q23; Region III, 14 cM, 10q26 (Moir et al., 1994) . Examples of the allelotype data of critical cases are shown in Figure 1b .
Localized microsatellite instability was observed in two cases. Case L28 showed a microsatellite instability at the locus D10S1686. Although we found additional LOH for this marker it does not justi®y the de®nition as a minimal region of deletion. Case L43 carried an instability for the D10S1782 along with additional LOH at six loci.
Generally, allelic imbalances were prevalent in metastatic carcinomas being present in 14 of 19 (74%) pM1 tumors whereas non-metastatic SCC showed LOH only in three of 20 cases (15%).
PTEN/MMAC1 gene
Direct DNA sequencing of the nine exons of the PTEN/MMAC1 gene was performed for 25 carcinomas with LOH at the chromosomal region 10q23-24, i.e. 12 SCLC, 12 lung SCC, one HNSCC cell line. No mutations were detectable. Furthermore no homozygous deletion was found at the marker Afm086 in 15 tumor cell lines (data not shown).
In addition, no rearrangements or deletions were identi®ed by Southern blot analysis of 13 tumor samples and 15 tumor cell lines (Figure 2a) .
The Northern blot analysis of 15 cancer cell lines and the RT ± PCR of the tumor cell lines and 20 primary tumors revealed the expression of the PTEN/ MMAC1 gene at similar levels and showed no altered transcripts or splicing variants (Figure 2b and c).
Discussion
In the present study, we performed a deletion mapping on chromosome 10q22-q26 in lung SCC to identify Figure 1 (a) Result of the allelotype analysis in the 17 lung carcinomas with allelic imbalances. The markers are listed without the pre®x D10S. Small numbers in between correspond to the genetic distance in cM. The black ellipses represent an LOH, whereas the shaded and empty ones indicate homozygosity and heterozygosity, respectively. The deletion mapping suggests three regions of minimal deletions that are located at the loci Afm086/D10S541, D10S185 and D10S1782/D10S169. Two localized microsatellite instabilities (msi) were observed for the markers D10S1686 and D10S1782. (b) Examples of critical cases with allelic imbalances showing the analysis of paired tumor (T) and normal (N) DNA samples from six patients candidate regions of tumor suppressor genes being involved in the tumor progression of lung cancer (Petersen et al., 1997a (Petersen et al., , 1998 . The analysis revealed three distinct regions of allelic imbalance. Allelic loss for the marker D10S541 which belongs to region I was observed particularly in prostate cancer (Gray et al., 1995; Komiya et al., 1996) . Ittmann (1996) reported deletions in prostate adenocarcinomas for a region surrounding the marker D10S185 which correlates with our second region.
Region III being located telomerically at 10q26 has been found in prostate cancer and endometrial carcinomas (Ittmann, 1996; Nagase et al., 1996) . Interestingly, allelic loss in endometrial cancer was associated with low grade and early stage malignancies (Nagase et al., 1996 (Nagase et al., , 1997 being in contrast to most other malignancies for which chromosome 10q deletions occurred preferentially in advanced tumor stages. Steck et al. (1995) suggested that the region 10q24-26 contains a tumor suppressor gene being relevant in glioblastomas. The distal 10q locus in glioblastomas was narrowed down to 10q25.1 between the markers D10S587 and D10S216 by Rasheed et al. (1995) . In general, the study con®rmed our previous ®nding that allelic loss on chromosome 10q is signi®cantly associated with the metastatic phenotype of lung SCC (Petersen et al., 1998) . The presence of LOH was generally higher in the pM1 cases and there was no obvious correlation between a single marker and primary or metastatic lesions. Interestingly, our recent CGH study on metastasizing and non-metastasizing HNSCC suggested that the telomeric chromosome 10q is signi®cantly associated with metastases formation (BockmuÈ hl et al., 1997) .
To our knowledge, three candidate tumor suppressor genes have been so far identi®ed on chromosome 10. The MXI1 gene has not yet been con®rmed as a tumor suppressor gene. In contrast to the initial observation (Eagle et al., 1995) no mutations were observed in a second study on prostate cancer (Gray et al., 1995) . We recently failed to identify mutations in lung cancer (Petersen et al., 1998) .
The PTEN/MMAC1 gene has been recently de®ned by two independent studies as a candidate tumor suppressor gene carrying mutations in prostate, breast, kidney and brain cancer (Steck et al., 1997; Li et al., 
two studies that it mediates Cowden disease, an autosomal dominant cancer predisposition syndrome associated with an elevated risk for tumors of the breast, thyroid and skin Nelen et al., 1997) . Cowden disease is linked to the marker D10S573 (Nelen et al., 1996) which indicate LOH for a subset of breast carcinomas (Kerangueven et al., 1997) . Sporadic breast carcinomas, however, carry PTEN/MMAC1 mutations only rarely (Rhei et al., 1997) and in one of the two primary tumors with mutations there was a medical history suggestive for Cowden disease. As recently shown, malignant melanoma cell lines and uncultured metastasis carry mutations (Guldberg et al., 1997) . However, the importance of this ®nding and the correlation to the Cowden phenotype is still unknown.
The fact that we neither observed a high incidence of LOH at the marker D10S573 nor identi®ed mutations of PTEN/MMAC1 in lung carcinomas suggest that this gene is not important for lung carcinogenesis. This observation was meanwhile con®rmed by a study in a wide variety of tumor types including lung carcinomas . In this regard it is important to note that lung cancer has a very distinct epidemiological background. The vast majority is related to smoking whereas the other cancer types with PTEN/ MMAC1 mutations do have a less precise etiology with genetic predisposition playing a more important role. Although patients with Cowden syndrome might present lung hamartomas malignant epithelial neoplasms are not parts of this cancer syndrome. The mutation pattern so far does not indicate a simple genotype ± phenotype relationship.
Most recently, the candidate gene DMBT1 has been identi®ed by the detection of homozygous deletions in medulloblastomas and glioblastomas (Mollenhauer et al., 1997) . Since it is located at chromosome 10q25.3-26.1 it is a strong candidate for region III. The analysis of this gene is currently in progress.
Microsatellite instability (MSI) was a rare ®nding in our study consistent with previous reports (Fong et al., 1995) . Interestingly, it was observed within regions of deletions suggesting that it might point to adjacent cancer-associated genes similar to allelic loss. Anyhow, it is important to distinguish between a localized MSI and the RER+ phenotype since the latter has been shown to constitute a distinct form of genomic instability (Lengauer et al., 1997) apart from chromosomal instability being typical for the majority of solid tumors including lung carcinomas.
In summary, we identi®ed three regions on chromosome 10q that are commonly deleted in human lung cancer. In our panel of tumors allelic imbalances were particularly associated with tumor progression and metastasis formation. Further studies are necessary to isolate and characterize the causative tumor suppressor genes in each of these regions.
Materials and methods
Tissue specimens and genomic DNA extraction
Squamous cell carcinoma of the lung used for allelotyping and SCLC specimens for mutational analyses were derived either from surgical resections at the Department of Surgery of the University Hospital ChariteÂ or from autopsies. Tumor and normal tissue were frozen in liquid nitrogen. DNA was extracted from several 30 mm cryostat tissue sections by proteinase K digestion and phenol/ chloroform extraction. The tumor tissue was veri®ed to consist of a minimum of 70% tumor cells in each case. We selected lung SCC for deletion mapping since this tumor entity harboured preferentially partial or interstitial deletions as shown by our previous study on 79 lung carcinomas using a limited number of markers (Petersen et al., 1998) . In total, 19 pM1 (cases L23-L40, L42) and 20 pM0 (L41, L43, L45-L62) lung cancer cases were investigated. In the pM1 cases, preferentially metastastic lesions were chosen for LOH analysis (except cases L33, L35 and L42). Fourteen head and neck squamous cell carcinomas (HNSCC) that were analysed by RT ± PCR for PTEN/MMAC1 expression were similarly obtained from surgical resections at the Department of Otorhinolaryngology of the ChariteÂ . Case numbers correspond to previously published data (Petersen et al., 1998) .
Tumor cell lines
Human lung carcinoma cell lines were purchased from the American Type Culture Collection (ATCC, Rockville, MD) and the German Collection of Microorganisms and Cell Culture (DSMZ, Braunschweig, Germany). These consisted of seven small cell lung carcinomas (COLO-668, COLO-677, CPC-N, H-378, H-187, H-526, N-417), two lung adenocarcinomas (COLO-699, DV-90) and one carcinoma of the lung without further speci®cation (A-427). All these cell lines carried a chromosomal alteration of chromosome 10 as determined by published data, FISH analysis with a chromosome 10 speci®c probe or by CGH. In addition, ®ve tumor cell lines analysed were established in our lab (unpublished data). They consisted of three HNSCC (D6, D36, D40) and two lung adenocarcinomas (D51 and D117). Of these, only the cell line D36 indicated a loss of chromosome 10q by CGH. The ®broblast cell line Wi-38 served as a positive control.
LOH analysis
Paired samples of tumor and normal DNA were assessed for allelic loss by microsatellite polymorphism analysis. Twenty-four dierent markers on chromosome 10q were selected from the GeÂ neÂ thon genetic map. Primer sequences were obtained from the genome database and commercially synthesized (MWG-Biotech, Ebersberg, Germany). For LOH-analysis one primer was labeled with the IRD41 infrared dye. PCRs were performed with approximately 100 ng DNA, 15 pmol of each primer and 200 mmol dNTPs. The DNA probes were denatured for 5 min and then ampli®ed by 35 cycles (1 min at 958C, 30 s at 558C and 30 s at 728C) followed by a ®nal extension step of 5 min at 728C. The annealing temperature was modi®ed for the marker D10S169 to 608C. PCR products were checked onto 1.5% agarose gels and then separated by 6% denaturing polyacrylamide gel electrophoresis (Biozym, Hess/Oldendorf, Germany) on a Licor automatic sequencer (MWG, Ebersberg, FRG) .
Scanoutput ®les of the sequencer were scored by an AMBA software. The software and the evaluation are exempli®ed at our web site http://amba.rz.charite.huberlin.de/cgh. LOH was determined when the allele of the tumor sample was less than 50% in comparison to the normal DNA.
Analysis of the MMAC1/PTEN gene
Northern blot Ten mg of total RNA were extracted from the tumor cell lines according to the phenol-guanidine Chromosome 10q in lung cancer S Petersen et al method (AGS, Heidelberg, Germany), were loaded onto a 1.5% agarose gels containing formaldehyde and run for 4 h at 60 V followed by overnight transfers onto nylon membranes (Amersham, Buckinghamshire, UK). PTEN/ MMAC1 cDNA probes were random-prime labeled with [ 32 P]-dCTP (Amersham). Filters were blocked in ExpressHyb (Clontech, Heidelberg, Germany) solutions at 628C, probes were added to the same solution and incubated overnight. Filters were washed twice in 26SSPE/0.1% SDS at room temperature and 16SSPE/ 0.1% SDS and 0.1% SSPE/0.1% SDS at 658C.
RT ± PCR Total RNA from surgically resected carcinomas, i.e. six lung carcinomas (L42, L43, L63, L75, L79, L80) and 14 HNSCC (HN27, HN28, HN29, HN30, HN37, HN44, HN65, HN67, HN71, HN72, HN73, HN74, HN92, HN122) was treated for 40 min at 378C with RQDNaseI (Promega, Madison, WI). First-strand cDNA was transcribed by 200 units super script II reverse transcriptase (Gibco, Eggenstein, Germany) from 10 mg of total RNA, in the presence of 16RT buer, 100 mM DTT, 20 units RNase inhibitor and 5 mM dNTPs (Promega), using the random hexamer primers (Promega). The reaction took place at 428C for 1 h followed by 15 min at 708C. The complete 1.2 kb PTEN/MMAC1 cDNA was ampli®ed in a 50 ml volume with 2.5 mM dNTPs and 20 pmol primers by 35 cycles (958C for 1 min, at 728C for 1 min and 608C for 2 min) and a ®nal extension step for 6 min with the following primer sequences for MMAC1: forward 5'-CCAGACATGACAGCCATC-3' and reverse 5'-TTTTTTCATGGTGTTTTATCCCTC-3'. Control was performed with commercially available b-Actin primers (Clontech).
Southern blot analysis Ten mg of genomic DNA of 13 tumors samples (L23, L29, L31, L36, L33, L34, L35, L37, L38, L39, L40, L42, L43) and the 15 cancer cell lines were digested overnight with BamHI and BglII (Boehringer Mannheim, Mannheim, Germany), respectively, using 60 units of restriction enzyme per sample. The DNA was loaded onto a 0.7% agarose gel, run for 4 h at 70 V and vacuum blotted for 90 min. Filters were hybridized and washed as described for Northern blot analysis.
Mutational analysis Published intronic primers were synthesized for amplifying exons 1 ± 9 . Direct cycle sequencing was performed on puri®ed PCR products using the described nested primer and the 33 P-dideoxylabeled terminator sequencing kit (Amersham, Buckinghamshire, UK). All products were sequenced twice using a forward and a reverse primer. The following carcinomas were analysed: 12 SCLCs, i.e. L2, L5, L6, L8, L9, L12, L13, L14, L18, L19, L20, L21; 12 SCCs, i.e. L23, L28, L29, L33, L34, L35, L37, L38, L39, L40, L42, L43; the HNSCC cell line D36.
Analysis for homozygous deletions
The 15 tumor cell lines were investigated for homozygous deletions of the locus Afm086. PCR was performed and products were separated onto a 6% polyacrylamide gel on a LiCOR automatic DNA sequencer.
Abbreviations CGH, Comparative Genomic Hybridization; FISH, Fluorescensce in situ hybridization; HNSCC, Head and neck squamous cell carcinoma; LOH, Loss of heterozygosity; MSI, Microsatellite instability; RER, Replication error repair; SCC, Squamous cell carcinoma; SCLC, Small cell lung carcinoma.
